Control of TGFβ signaling by km23 superfamily members

Abstract

Methods of identifying therapeutic agents that inhibit, potentiate or mimic the ability of a km23 polypeptide mutant form, or a nucleic acid encoding the mutant form to modulate the signal transduction activity of a growth factor or cytokine are provided. The methods involve treating a cell with a candidate compound so as to alter at least one cell process associated with the TGFβ signaling pathway, and measuring the effect of the candidate on the cell. Further provided are cell and non-cell based methods of screening for a therapeutic agent that inhibits or stimulates the interaction of an altered form of wild-type km23 with a specific binding protein, such as the dynein intermediate chain (DIC), Smad2 or RI and RII TGFβ receptors. These methods involve determining the inhibition or stimulation of a therapeutic candidate on the interaction of the specific binding protein with the km23 altered form. The km23 mutant/altered forms of the methods of the present invention indicate an increased risk of ovarian cancer.

Dependencies are inferred from the claim text.